Background. Hepatitis C virus (HCV) entry involves scavenger receptor B1 (SRB1). In vitro, SRB1 inhibition by ITX5061 impedes HCV replication.Methods. Multicenter study to assess safety/activity of ITX5061 in previously untreated, noncirrhotic, HCV genotype 1 infected adults. Design included sequential cohorts of 10 subjects with ITX5061 (n = 8) or placebo (n = 2) to escalate duration (3 to 14 to 28 days) or deescalate dose (150 to 75 to 25 mg) based on predefined criteria for safety and activity (≥4 of 8 subjects with HCV RNA decline ≥1 log10 IU/mL).Results. Thirty subjects enrolled in 3 cohorts: ITX5061 150 mg/day by mouth for 3 (A150), 14 (B150), and 28 (C150) days. Six subjects had grade ≥3 adverse events (one in placebo); none were treatment related. One of the 7 C150 subjects (14.3%, 95% confidence interval [CI], .7%-55.4%) had ≥1 log10 IU/mL decline in HCV RNA (1.49 log10 IU/mL), whereas none of the 6 placebo, 8 A150 or 8 B150 subjects showed such decline.Conclusions. Oral ITX5061 150 mg/day for up to 28 days was safe and well tolerated. In the 28-day cohort, 1 of 7 subjects showed antiviral activity; however, predefined criteria for antiviral activity were not met at the doses and durations studied.

Background. Hepatitis E virus (HEV) infection causes major epidemics of infectious hepatitis, with high mortality rates in pregnant women. Recent reports indicate that HEV coinfections with human immunodeficiency virus (HIV) may have a more protracted course. However, the impact of HEV infections in communities heavily affected by HIV remains poorly studied. We set out to examine age-related seroprevalence in a community where we have previously carried out studies on environmental enteropathy.Methods. Blood samples from 194 children and 106 adults were examined for immunoglobulin G and immunoglobulin M antibodies for HEV. HEV data were correlated with HIV status and morphometric analysis of small intestinal biopsies.Results. Seroprevalence rose throughout childhood, from 8% in children aged 1-4 years, to 36% in children aged 10-14 years. In adults, the overall prevalence was 42%, with 28% in HIV-seronegative adults and 71% in HIV-seropositive adults (odds ratio, 6.2; 95% confidence interval, 2.2-18; P = .0001). In adults, villous height and crypt depth measurements showed that HEV seropositivity was associated with worse enteropathy (P = .05 and P = .005, respectively).Conclusions. HEV infection is common in Zambia. In adults it is strongly associated with HIV status, and also with environmental enteropathy.

= 0.72，95%CI：0.57～0.91，P = 0.005）和缺血性卒中（HR = 0.73，95%CI：0.57～0.93，P = 0.01）风险，且未增加出血性卒中风险（HR = 0.83，95%CI：0.42～1.6，P = 0.59）。对于是否合并脑血管病史的患者，阿利西尤单抗的作用相似（交互 P = 0.37）；对于

为32%（95%CI为[27，37]），根据样本来源进行分层后，发现社区样本相应总体发病率为25%（95%CI为[19，30]），临床样本相应总体发病率则为40%（95%CI为[32，48]），社区样本和临床样本总体发病率间有显著统计学差异（P＜0.001）。研究通过分析得到的MCI患者抑郁总体发病率与以往相似研究所

，电话同上，E-mail:Z2eye@sina.com四、截稿日期： 中文2010年1月30日，英文2010年3月30日（以邮戳为准）截止。过期恕不

比值 (FCPGR)。随访结果显示，与安慰剂组相比，二甲双胍组患者的 FCPGR 升高 1.48 (95% CI: 1.09-1.87, P < 0.001... 例使用二甲双胍者和 1932 例使用胰岛素者，两组孕妇平均年龄均为 32±5 岁。分析结果显示，经调整混杂因素后，二甲双胍组后代体重与身高 z 分数值与胰岛素组

(25日安排讲座，26-28日为系统综述课程)优惠条件： 7月15日前交费个人享受95折优惠；团体（三人以上）享受95折优惠

主办单位：生物谷、诺沃兰Normalline时间：2012年6月8-9日地点：上海万豪明天广场网址：www.bioon.com/z/IVD&MD关于培训：生物谷应广大会员企业要求，特别邀请医疗器械领域资深服务公司诺沃兰Normalline—

负荷，血糖指数，糖尿病，IGF-1,空腹血糖，空腹胰岛素和C肽，脂联素，二甲双胍和甘精胰岛素的使用。总相对危险（SRR）和相应的95%置信区间（CI）被计算出来。结果：对于所有年龄段的乳腺癌来说，这些计算出的风险如下：糖尿病(SRR51.23 95% CI (1.12, 1.34)）；体育运动(SRR50.88

) ADF/cofilin: a functional node in cell biology. Trends Cell Biol.20(4), 187–95.Hung RJ, Yazdani U, Yoon J, Wu H, Yang T, Gupta N, Huang Z, van Berkel WJ, Terman JR

, Y., Gao, Z., Li, E., Li, X., Zhang, W., Wang, J., Xu, L., Zhou, Y., et al.... Nature 509, 91-95.查看参考文献>>

抗 DNA 抗体的发现抗 DNA 抗体分为抗双链 DNA（ds-DNA）抗体、抗单链 DNA（ss-DNA）抗体和抗 Z-DNA 抗体。抗 ds-DNA 抗体的靶抗原是细胞核中的 DNA 双螺旋结构；抗 ss-DNA 抗体靶抗原是核糖、脱氧核糖；抗 Z-DNA 抗体的靶抗原是左双螺旋 DNA。一般来说

：13361952955大会官网：www.bioon.com/z/lsacforum/